SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059068
Filing Date
2024-05-14
Accepted
2024-05-14 06:42:01
Documents
79
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q syrs-20240331.htm   iXBRL 10-Q 1411378
2 EX-10.1 syrs-ex10_1.htm EX-10.1 37157
3 EX-31.1 syrs-ex31_1.htm EX-31.1 14871
4 EX-31.2 syrs-ex31_2.htm EX-31.2 14977
5 EX-32.1 syrs-ex32_1.htm EX-32.1 7365
6 EX-32.2 syrs-ex32_2.htm EX-32.2 7334
  Complete submission text file 0000950170-24-059068.txt   7805405

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT syrs-20240331.xsd EX-101.SCH 1493130
83 EXTRACTED XBRL INSTANCE DOCUMENT syrs-20240331_htm.xml XML 1227236
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 24941395
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)